Mo-Fan Huang received her Master's degree from National Tsing Hua University in Taiwan in 2019 and is now pursuing a Ph.D. at the University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences in the US. She worked in Drs. Dung-Fang Lee and Ruiying Zhao’s labs in McGovern Medical School at the University of Texas Health Science Center in Houston (UTHealth Houston) as a research assistant from 2020 to 2021. In 2021, she enrolled in the University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences and began pursuing a Ph.D. in Dr. Dung-Fang Lee’s lab. Her research topics mainly include investigating the role of RB1 tumor suppressor in osteosarcoma (OS) development using the patient-derived induced pluripotent stem cells (iPSC) platform.

Yuan-Xin Wang received her B.S. degree in Medical Science from National Tsing-Hua University in 2021. Currently, she is actively pursuing her Ph.D. in the program of Bio-industrial Technology at the same university. Since 2020, she has dedicated herself to her doctoral studies under the guidance of Dr. Yu-Ting Chou, where she explores the intricate realms of cancer heterogeneity and the non-canonical function of RB1. Additionally, she contributed as a coauthor to a publication in the International Journal of Cancer in 2022. In her pursuit of knowledge and practical experience, Yuan-Xin embarked on a rewarding internship journey supported by the Overseas Internship Program (Taiwan Ministry of Education) and the Shen’s Culture & Education Foundation Scholarship from September 2023 to February 2024. During this period, she had the privilege of joining Dr. Dung-Fang Lee's lab at the University of Texas Health Science Center in Houston. This invaluable opportunity allowed her to delve into new methodologies, broaden her scientific horizons, and forge connections with leading experts in the field.

Dr. Yu-Ting Chou is affiliated with the Institute of Biotechnology at National Tsing Hua University. He spearheaded a project focusing on cancer heterogeneity and RB1 non-canonical function. With an impressive publication record of 50 papers across various journals, Dr. Chou also holds leadership roles as a chair for the Ph.D. program in precision medicine at National Tsing Hua University and for transdisciplinary projects related to precision medicine. His teaching expertise encompasses medical genetics, while his research interests delve into cancer metabolism and targeted therapy.

Dr. Dung-Fang Lee is an Associate Professor in the Department of Integrative Biology and Pharmacology, McGovern Medical School, University of Texas Health Science Center, Houston, TX, USA. He obtained his Bachelor’s and Master’s degrees from the National Tsing Hua University, Taiwan in 1994 and 1996, respectively. He then obtained his Ph.D. in Oncology and Cancer Biology from the M.D. Anderson Cancer Center, The University of Texas Health Science Center, Houston, in 2008, and completed his postdoctoral studies at the Icahn School of Medicine at Mount Sinai in 2016. Dr. Lee’s research is dedicated to understanding cancer pathological mechanisms with iPSC disease models. His laboratory has tremendous interest and experience in collaborating with clinical physicians to merge innovative iPSC disease models and patient-derived resources such as PDXs, patient specimens, single cell transcriptome, and TCGA and TARGET databases towards garnering molecular insights into cancer initiation, development, and therapeutic resistance and translating these findings towards testing novel therapeutic interventions for malignancies (e.g., mutant p53-associated cancers and RB1-depleted cancers). They have established several iPSC models to delineate the pathological mechanisms of cancer-prone genetic disorders, including Li–Fraumeni syndrome, hereditary retinoblastoma, and Rothmund–Thomson syndrome.